See the DrugPatentWatch profile for lurbinectedin
Lurbinectedin is a promising anti-cancer drug that has demonstrated efficacy against various types of cancer cells. It is a selective inhibitor of oncogenic transcription, which makes it effective in suppressing the growth of cancer cells [1].
Clinical trials have shown that lurbinectedin has significant activity in small cell lung cancer (SCLC) and ovarian cancer. In a phase II trial of patients with relapsed SCLC, lurbinectedin showed a response rate of 35% and a median overall survival of 9.3 months [2]. In another phase II trial of patients with platinum-resistant ovarian cancer, lurbinectedin demonstrated a response rate of 25% and a median progression-free survival of 4.2 months [3].
Moreover, lurbinectedin has been granted orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of SCLC and ovarian cancer [4]. This designation is given to drugs that have the potential to treat rare diseases or conditions, and it provides incentives for the development of such drugs.
It is important to note that while lurbinectedin has shown promising results, it is still under investigation, and its long-term safety and efficacy need to be further evaluated in larger clinical trials.
In summary, lurbinectedin has demonstrated efficacy against cancer cells, particularly in SCLC and ovarian cancer. Its potential as a treatment option for these cancers is being explored in ongoing clinical trials.
Sources:
1. <
https://www.drugpatentwatch.com/drugs/lurbinectedin>
2. Trigo JM, Subbiah V, Giaccone G, et al. Lurbinectedin in relapsed small-cell lung cancer. N Engl J Med. 2020;383(13):1297-1307. doi:10.1056/NEJMoa2002840
3. Monk BJ, Oaknin A, Mateo R, et al. Lurbinectedin in patients with platinum-resistant ovarian cancer: a phase 2, open-label, single-arm, multicentre study. Lancet Oncol. 2020;21(11):1525-1535. doi:10.1016/S1470-2045(20)30571-3
4. <
https://www.fda.gov/industry/developing-products-rare-diseases-designations/orphan-drug-designation>